SCHEMBL1648574

SCHEMBL1648574

COC(=O)c1c(CS(=O)(=O)c2ccccc2)ccc(-c2ccoc2)c1NCc1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.39
ALDH1A1 P00352 6/20 0.38
CYP1A2 P05177 4/20 0.38
CYP3A4 P08684 4/20 0.38
CYP2D6 P10635 4/20 0.38
HSD17B10 Q99714 3/20 0.38
CLK4 Q9HAZ1 3/20 0.38
TSHR P16473 3/20 0.38
CYP2C19 P33261 3/20 0.38
CYP2C9 P11712 1/20 0.38
KMT2A Q03164 6/20 0.36
MEN1 O00255 5/20 0.36
USP2 O75604 3/20 0.36
NAT1 P18440 2/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
METAP2 P50579 1/20 0.36
MAPT P10636 2/20 0.35
KDM4E B2RXH2 1/20 0.35
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1648197 0.88 METAP2 (0.38) KMT2ANAT1METAP2KDM4EPOLB
SCHEMBL6844888 0.84 NAT1 (0.40) KMT2AMEN1NAT1METAP2POLB
SCHEMBL1648290 0.84 METAP2 (0.39) HSD17B10KMT2AMEN1USP2NAT1
SCHEMBL1648203 0.83 METAP2 (0.39) ALDH1A1KMT2AMEN1NAT1METAP2
SCHEMBL1649273 0.83 MALT1 (0.39) ALDH1A1HSD17B10NAT1CA1CA2
SCHEMBL1650005 0.82 METAP2 (0.40) KMT2ANAT1METAP2POLB
SCHEMBL18801500 0.82 ALDH1A1 (0.39) ALOX5ALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL1648987 0.82 METAP2 (0.36) NAT1METAP2KDM4EPOLB
SCHEMBL1648537 0.79 METAP2 (0.40) ALDH1A1CYP1A2CYP3A4TSHRKMT2A
SCHEMBL18801088 0.79 NAT1 (0.34) ALOX5ALDH1A1CYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2486004-B1 SULPHONE COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY ZAFGEN INC (US) 2017-05-03 EP disclosed
EP-2486004-B1 SULPHONE COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY ZAFGEN INC (US) 2017-05-03 EP disclosed
US-20160051531-A1 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN INC (US) 2016-02-25 US disclosed
US-9067905-B2 Sulphone compounds and methods of making and using same ZAFGEN, INC. (US) 2015-06-30 US disclosed
US-9067905-B2 Sulphone compounds and methods of making and using same ZAFGEN, INC. (US) 2015-06-30 US disclosed
US-9067905-B2 Sulphone compounds and methods of making and using same ZAFGEN, INC. (US) 2015-06-30 US disclosed
US-20130053364-A1 Sulphone Compounds and Methods of Making and Using Same ZAFGEN, INC. 2013-02-28 US disclosed
US-20130053364-A1 Sulphone Compounds and Methods of Making and Using Same ZAFGEN, INC. 2013-02-28 US disclosed
US-20130053364-A1 Sulphone Compounds and Methods of Making and Using Same ZAFGEN, INC. 2013-02-28 US disclosed
EP-2486004-A2 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME Zafgen Corporation (US) 2012-08-15 EP disclosed
WO-2011044506-A2 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN CORPORATION (US) 2011-04-14 WO disclosed
WO-2011044506-A2 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN CORPORATION (US) 2011-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160051531-A1 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME METAP2, DNPEP, STS ALOX5 951/4885ALDH1A1 360/4885CYP1A2 300/4885
US-20130053364-A1 Sulphone Compounds and Methods of Making and Using Same METAP2, DNPEP, STS ALOX5 951/4885ALDH1A1 360/4885CYP1A2 300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.